Patents Issued in August 14, 2018
  • Patent number: 10046043
    Abstract: The present invention generally provides methods and compositions for eliciting an immune response against Neisseria spp. bacteria in a subject, particularly against a Neisseria meningitidis serogroup B strain.
    Type: Grant
    Filed: August 15, 2016
    Date of Patent: August 14, 2018
    Assignee: CHILDREN'S HOSPITAL & RESEARCH CENTER AT OAKLAND
    Inventors: Dan M. Granoff, Victor Chen-Hsi Hou
  • Patent number: 10046044
    Abstract: A CyaA-deficient B. pertussis mutant was constructed and used in a vaccine. The pertussis-specific antibody profile and Th17 response induced by vaccination with the mutant was surprisingly comparable to that induced by B. pertussis strains not deficient in CyaA.
    Type: Grant
    Filed: April 3, 2017
    Date of Patent: August 14, 2018
    Assignees: National University of Singapore, Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Pasteur de Lille
    Inventors: Sylvie Claudette Alonso, Rui Fen Annabelle Lim, Camille Locht
  • Patent number: 10046045
    Abstract: The present disclosure relates to nonstructural protein 1 (NS1) from flaviviruses and uses thereof. In particular, the present invention relates to diagnostic and therapeutic uses of NS1 to treat and prevent disease caused by flaviviruses.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: August 14, 2018
    Assignees: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, PURDUE RESEARCH FOUNDATION
    Inventors: Janet L. Smith, David L. Akey, W. Clay Brown, Richard J Kuhn
  • Patent number: 10046046
    Abstract: The invention relates to amino sphingoglycolipid analogues and peptide derivatives thereof, compositions comprising these compounds and methods of treating or preventing diseases or conditions using such compounds, especially diseases or conditions relating to cancer, infection, atopic disorders, autoimmune disease or diabetes.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: August 14, 2018
    Assignee: Victoria Link Limited
    Inventors: Regan James Anderson, Benjamin Jason Compton, Colin Malcolm Hayman, Ian Francis Hermans, Karen Anne Johnston, Gavin Frank Painter
  • Patent number: 10046047
    Abstract: Compositions and methods for co-expressing a secretable vaccine protein (such as gp96-Ig) and T-cell co-stimulatory molecules from a single vector, among others, are provided herein. Materials and methods for using gp96-Ig vaccination and T-cell co-stimulation to treat a clinical condition (e.g., cancer) in a subject also are provided.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: August 14, 2018
    Assignee: Heat Biologics, Inc.
    Inventors: Taylor Schreiber, George Fromm
  • Patent number: 10046048
    Abstract: The present invention generally relates to homogeneous suspensions of small molecule immune potentiators (SMIPs) that are capable of stimulating or modulating an immune response in a subject in need thereof. The homogeneous suspensions may be used in combinations with various antigens or adjuvants for vaccine therapies.
    Type: Grant
    Filed: July 5, 2016
    Date of Patent: August 14, 2018
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: David Skibinksi, Siddhartha Jain, Manmohan Singh, Derek O'Hagan
  • Patent number: 10046049
    Abstract: This invention relates to the field of therapeutics. Most specifically invention provides methods of generating in vitro engineered immune cells conditionally expressing interleukin-12 (IL-12) and one or more immunomodulators under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: August 14, 2018
    Assignee: Intrexon Corporation
    Inventors: Robert P. Beech, Thomas D. Reed
  • Patent number: 10046050
    Abstract: Disclosed are methods and compositions for targeting antibodies to amyloid deposits. For example, amyloid-reactive peptides that bind amyloid deposits are administered to a subject. Antibodies to the amyloid-reactive peptides are then administered to the subject. Upon administration of the antibodies, the amyloid-reactive peptides bind the antibodies and thus pre-target the antibodies to the amyloid deposits. In other examples, an amyloid-reactive fusion peptide contains an epitope of a known antibody. When the fusion peptide is administered to a subject, the fusion peptide binds amyloids in the subject. Administration to the subject of the known antibody that binds the epitope of the fusion peptide then targets the antibody to the amyloid deposit to which the fusion peptide is bound.
    Type: Grant
    Filed: February 24, 2016
    Date of Patent: August 14, 2018
    Assignee: UNIVERSITY OF TENESSEE RESEARCH FOUNDATION
    Inventors: Jonathan S. Wall, Stephen J. Kennel, James S. Foster
  • Patent number: 10046051
    Abstract: A drug carrier and a method of using the same are provided, wherein the drug carrier includes a base made of a carbon fiber which is magnetic and has a first polarity, a positioning member connected to the base, and is adapted to be positioned and move to a target location by guiding of at least an energy field, and a connector connected to the positioning member and a drug with two ends respectively, wherein the connector has a second polarity opposite to the first polarity, and is recognized by an organism and digested in the organism. The method includes the steps of: injecting the drug carrier into an organism; positioning the drug carrier to a target location within the organism by an equipment; and releasing the drug from the drug carrier by an external energy.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: August 14, 2018
    Assignee: LINKWIN TECHNOLOGY CO., LTD.
    Inventor: Yi-Ching Cheng
  • Patent number: 10046052
    Abstract: Methods and dosage formulations for the safe treatment of cold, cough, flu, and sinus symptoms in children and adolescents by age and nature of symptoms, and adults and the elderly by age, nature of symptoms, and concomitant patient medical conditions. The method of the present invention comprises the formulation of a cold medication which consists essentially of combinations of a nonsedating or minimally sedating antihistamines with pain relievers and the expectorant, guaifenesin.
    Type: Grant
    Filed: May 16, 2011
    Date of Patent: August 14, 2018
    Inventor: Bernard Silverman
  • Patent number: 10046053
    Abstract: The invention relates to compositions comprising (i) biocompatible hydrogel and (ii) one or more therapeutic agents contained within said hydrogel; wherein the hydrogel is cross-linked utilizing a cross-linker comprising a peptide sequence that is capable of being degraded by an enzyme; the therapeutic agent being effective as a treatment of a condition related to the presence of the enzyme.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: August 14, 2018
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Brendan Patrick Purcell, Jason Alan Burdick
  • Patent number: 10046054
    Abstract: Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: August 14, 2018
    Assignee: Purdue Research Foundation
    Inventors: Philip S. Low, Sumith A. Kularatne
  • Patent number: 10046055
    Abstract: The present invention provides novel bisphosphonate conjugates, pharmaceutical compositions comprising bisphosphonate conjugates and methods of using such analogs in the treatment of bone cancer, bone-related diseases, bone infection, bone inflammation, and diseases of the soft tissues surrounding bones.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: August 14, 2018
    Assignee: MBC PHARMA, INC.
    Inventors: Alexander Karpeisky, Shawn Patrick Zinnen
  • Patent number: 10046056
    Abstract: Several embodiments of the present disclosure relate to glycotargeting therapeutics that are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent. In several embodiments, the compositions are configured to target the liver and deliver antigens to which tolerance is desired. Methods and uses of the compositions for induction of immune tolerance are also disclosed herein.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: August 14, 2018
    Assignee: École Polytechnique Fédérale de Lausanne (EPFL)
    Inventors: Jeffrey A. Hubbell, David Scott Wilson
  • Patent number: 10046057
    Abstract: There are disclosed compositions and methods to render nucleic acids resistant to nuclease digestion while maintaining sequence selective hybridization competency. The approach relies on utilizing nucleic acids as the polar head group of a nucleic acid-polymer amphiphile in order to assemble well-defined, discrete micellar nanoparticles. Dense packing of nucleic acid in the micelle corona allows for hybridization of complementary oligonucleotides while prohibiting enzymatic degradation.
    Type: Grant
    Filed: March 24, 2015
    Date of Patent: August 14, 2018
    Assignee: The Regents of the University of California
    Inventors: Erick T. Tatro, Nathan Gianneschi, Anthony M. Rush
  • Patent number: 10046058
    Abstract: Examples may include a microsphere. The microsphere may include a biodegradable polymer. Furthermore, the microsphere may include a protein mixture selected from the group consisting of a protein-polyethylene glycol conjugate, the protein-polyethylene glycol conjugate and the hydrophobic anion of the organic acid, a protein and the hydrophobic anion of the organic acid, and combinations thereof. Examples may also include a method of making the microspheres. The method may further include reacting a polyethylene glycol with a protein to form a protein-PEG conjugate. In addition, the method may include protonating an amino group on the protein-PEG conjugate with a hydrophobic organic acid to form the protein-PEG conjugate salt. Furthermore, the method may include mixing the protein-PEG conjugate salt in an organic solvent with a biodegradable polymer. The method may also include emulsifying the mixture.
    Type: Grant
    Filed: November 30, 2015
    Date of Patent: August 14, 2018
    Assignee: REZOLUTE, INC.
    Inventors: Mary S. Rosendahl, Sankaram B. Mantripragada, Eliana B. Gomez
  • Patent number: 10046059
    Abstract: Disclosed herein are an N-terminal modified PEG-TRAIL conjugates and methods of making and using thereof. The PEG-TAIL conjugates have bioactivity that is substantially similar to that of native TRAIL coupled with an extended in vivo half-life and enhanced stability. The disclosed PEG-TRAIL conjugates exhibit significantly reduced hepatotoxicity when compared to that of non-PEGylated trimeric TRAIL. The disclosed methods of making the PEG-TRAIL conjugates provide a homogeneous, highly pure, form of N-terminal modified PEG-TRAIL. Compared to native TRAIL, the PEG-TRAIL conjugates exhibits high solubility and solution stability. The PEG-TRAIL conjugates are useful in preventing and treating proliferative or autoimmune diseases.
    Type: Grant
    Filed: April 25, 2016
    Date of Patent: August 14, 2018
    Assignee: D&D Pharmatech Inc.
    Inventors: Kang Choon Lee, Seulki Lee, Eun Ji Park
  • Patent number: 10046060
    Abstract: The invention provides methods of delivering pharmacologic agents linked to an internalization peptide, in which an inflammatory response inducible by the internalization peptide is inhibited by co-administration of an anti-inflammatory or by linking the internalization peptide to biotin or similar molecule. Such methods are premised in part on the results described in the examples whereby administration of a pharmacological agent linked to tat at high dosages is closely followed by an inflammatory response, which includes mast cell degranulation, histamine release and the typical sequelae of histamine release, such as redness, heat, swelling, and hypotension.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: August 14, 2018
    Assignee: NoNO INC.
    Inventors: Michael Tymianski, Jonathan David Garman, Hong Cui
  • Patent number: 10046061
    Abstract: Provided are an insulin conjugate having improved insulin receptor binding affinity and increased activity, in which a non-peptidyl polymer and an immunoglobulin Fc region are site-specifically linked to an amino acid residue of the insulin beta chain excluding the N-terminus thereof via a covalent bond, a long-acting formulation including the same, and a preparation method thereof. The insulin conjugate of the present invention is used to provide an insulin formulation which exhibits a remarkably increased in vivo activity of the peptide.
    Type: Grant
    Filed: February 26, 2014
    Date of Patent: August 14, 2018
    Assignee: HANMI PHARM. CO., LTD
    Inventors: Myung Hyun Jang, Dae Jin Kim, Sang Youn Hwang, Hyun Uk Kim, Sung Youb Jung, Se Chang Kwon
  • Patent number: 10046062
    Abstract: A retractor assembly comprising a spool configured to wind and unwind the webbing, a lock base, and an energy absorbing member having a first end operatively connected to the locking base and a second end operatively connected to the spool. The energy absorbing member provides a progressive level of load resistance upon relative rotation between the spool and the locking base.
    Type: Grant
    Filed: October 18, 2012
    Date of Patent: August 14, 2018
    Assignee: JOYSON SAFETY SYSTEMS ACQUISITION LLC
    Inventor: Gary Lee Stroik, Jr.
  • Patent number: 10046063
    Abstract: Conjugates and compounds for making conjugates which are PBD molecules linked via the N10 position are disclosed, along with the use of the conjugates for treating proliferative diseases, including cancer.
    Type: Grant
    Filed: January 26, 2017
    Date of Patent: August 14, 2018
    Assignee: IMMUNOGEN, INC.
    Inventors: Ravi V. J. Chari, Michael Louis Miller
  • Patent number: 10046064
    Abstract: Provided herein are methods and related compositions for administering viral transfer vectors and antigen-presenting cell targeted immunosuppressants.
    Type: Grant
    Filed: September 7, 2015
    Date of Patent: August 14, 2018
    Assignee: Selecta Biosciences, Inc.
    Inventor: Takashi Kei Kishimoto
  • Patent number: 10046065
    Abstract: A nucleic acid-encapsulating polymer micelle complex is formed of a block copolymer containing an uncharged hydrophilic polymer chain block and a cationic polymer chain block; and two single-stranded DNA molecules having mutually complementary base sequences of 1000 or more bases in length, double-stranded DNA of 1000 or more base pairs in length in which at least a part of a double helix structure is dissociated and forms a single-stranded structure, or one single-stranded DNA molecule of 1000 or more bases in length.
    Type: Grant
    Filed: August 5, 2014
    Date of Patent: August 14, 2018
    Assignee: Japan Science and Technology Agency
    Inventors: Kazunori Kataoka, Kensuke Osada, Theofilus Agrios Tockary
  • Patent number: 10046066
    Abstract: Provided herein is chitosan-derivative nanoparticle comprising chitosan functionalized with a cationic amino acid and a hydrophilic polyol; and methods of making and using same, e.g., for gene delivery in vivo.
    Type: Grant
    Filed: September 25, 2014
    Date of Patent: August 14, 2018
    Inventors: Jun Gao, Eric Hsu, Anthony Cheung
  • Patent number: 10046067
    Abstract: The present invention relates to a novel gene delivery system and recombinant adenovirus comprising the decorin-encoding sequence to enhance transduction efficiency of transgenes, a pharmaceutical anti-tumor composition comprising the recombinant adenovirus, a pharmaceutical composition having improved tissue penetration potency and a pharmaceutical composition for treating a disease or disorder associated with accumulation of excess extracellular matrix.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: August 14, 2018
    Assignee: GENEMEDICINE CO., LTD.
    Inventors: Chae-Ok Yun, Joo Hang Kim
  • Patent number: 10046068
    Abstract: This invention relates to compounds comprising a saccharide conjugated to an imaging agent or a reporter group, compositions comprising them and methods of using them. Specifically BLM-disaccharide and BLM-monosaccharide conjugates containing different linker groups and an imaging agent or a reporter group are provided for the targeting and imaging of tumors.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: August 14, 2018
    Assignee: Arizona Board of Regents on behalf of Arizona State University
    Inventors: Sidney Hecht, Manikandadas Mathilakathu Madathil, Chandrabali Bhattacharya, Trevor Bozeman, Rakesh Paul, Zhiqiang Yu, Michael J. Rishel
  • Patent number: 10046069
    Abstract: The invention is directed to bodies comprising an amorphous carbon particle on which are supported nanoparticles of an oxide of lanthanide. These bodies find use as a pharmaceutical for use in a surgery or therapy and diagnostic methods. The bodies can be made by a process comprising impregnating a carbon source material by contacting it with a solution of a salt of the lanthanide; drying the impregnated carbon source material; and subjecting the dried impregnated material to pyrolysis under inert conditions.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: August 14, 2018
    Assignee: BASF Corporation
    Inventors: Jacobus Hoekstra, Eefjan Breukink, Leonardus Wijnand Jenneskens, John Wilhelm Geus
  • Patent number: 10046070
    Abstract: According to one implementation a central venous catheter is provided that include a main shaft and an infusion shaft. The main shaft has a proximal end, a distal end and a working lumen, the distal end configured for placement inside a patient. The infusion shaft has a proximal end, a distal end and a working lumen. The assembly further includes an optical fiber that is configured to emit bacterial disinfecting light. The distal end of the infusion shaft is coupled to the proximal end of the main shaft by a conduit located inside a hub. The conduit fluidly connects the working lumen of the infusion shaft with the working lumen of the main shaft. The hub has a channel that houses at least a portion of the length of the optical fiber.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: August 14, 2018
    Assignee: Inikoa Medical, Inc.
    Inventors: Brett M. Zaborsky, Michael R. Lopez
  • Patent number: 10046071
    Abstract: The invention relates to a continuous sterilizing system comprising a sterilizing body into which a thermal fluid is introduced for sterilizing products, the products to be sterilized being arranged in containers that circulate inside the sterilizing body, said sterilizing body being divided into different sterilization zones by means of dividing walls, and each of said dividing walls having a through-opening that is substantially the same shape as a container, such that the containers close the through-openings of the dividing walls, rendering the sterilization zones thermally isolated from one another.
    Type: Grant
    Filed: February 13, 2014
    Date of Patent: August 14, 2018
    Assignee: SURDRY, S.L.
    Inventor: Jose Vicente Bertomeu Asategui
  • Patent number: 10046072
    Abstract: A sterilization apparatus is disclosed for sterilization of objects. The sterilization apparatus includes a chamber for receiving the objects, the chamber including a sterilization medium inlet and outlet; an inlet flow control device for controlling a supply of a sterilization medium to the chamber; a drain system for controllable discharge of fluid from the chamber; and a control unit configured to control the inlet flow control device and drain system in accordance with a sterilization scheme. The drain system includes: a drain inlet connected to the sterilization medium outlet; a drain outlet connected to a vacuum system for evacuating the chamber; a first conduit connecting the drain inlet and outlet; and a proportional valve, arranged along the first conduit, controllable by the control unit to partly restrict fluid flow through the first conduit according to a continuous relation between a control parameter and a valve opening of the proportional valve.
    Type: Grant
    Filed: June 18, 2012
    Date of Patent: August 14, 2018
    Assignee: GETINGE STERILIZATION AB
    Inventors: Bengt Storberg, Stefan Troedsson
  • Patent number: 10046073
    Abstract: Provided herein are portable ultraviolet (UV) devices, systems, and methods of use and manufacturing same. Methods of use include methods for UV disinfection and sterilization, more specifically, methods for UV disinfection and sterilization of a container, a room, a space or a defined environment. The portable UV devices, systems and methods are particularly useful for the UV disinfection and sterilization of a container, a room, a space or defined environment used in the food, beverage and dairy industry and in the process of fermentation for an alcoholic beverage. Provided are also portable UV devices, systems, and methods for inhibiting the growth of one or more species of microorganisms present in a container, a room, a space or a defined environment, preferably for inhibiting the growth of one or more species of microorganisms present on an interior surface of a container, a room, a space or a defined environment.
    Type: Grant
    Filed: July 29, 2015
    Date of Patent: August 14, 2018
    Assignee: BlueMorph, LLC
    Inventors: Alexander Farren, Noah Bareket, Thomas Edgar Beard
  • Patent number: 10046074
    Abstract: A sterilizer may include: a first pipe having an inner wall with a light reflecting property; a second pipe disposed in the first pipe so as to pass fluid therethrough and formed of a light transmitting material; and a plurality of UV LEDs arranged on the inner wall of the first pipe and configured to irradiate sterilization UV light onto the fluid.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: August 14, 2018
    Assignee: Seoul Viosys Co., Ltd.
    Inventors: Seong Min Lee, Young Hwan Son, Jae Seon Yi, Jong Rack Kim, Ik Hwan Ko
  • Patent number: 10046075
    Abstract: A device for transmitting and projecting greater photonic energy. The device includes at least one photonic source for generating and emitting photonic energy in a wavelength or in a range of wavelengths of visible light. The device also includes a lens formed of a fluoropolymer material wherein the at least one photonic source is sealed within an interior and underneath an outer surface of the fluoropolymer material so as to be surrounded by the fluoropolymer material. The at least one photonic source is coupled with the lens such that the photonic energy emitting from the at least one photonic source transmits through and projects beyond the fluoropolymer material. The lens propagates photons in an omnidirectional pattern simultaneously throughout the entirety of the lens. The joining of the at least one photonic source and the fluoropolymer material comprises all components for generating and emitting photonic energy when the photonic source is activated, such that it is an operable source.
    Type: Grant
    Filed: February 20, 2017
    Date of Patent: August 14, 2018
    Assignee: Violet Defense Technology, Inc.
    Inventors: Mark Nathan, Theresa Nathan
  • Patent number: 10046076
    Abstract: Embodiments of the invention include an ultraviolet (UV) source, the UV source including a semiconductor device comprising an active layer disposed between an n-type region and a p-type region. The active layer emits radiation having a peak wavelength in a UV range. A reflector cup is disposed around the UV source. A transparent cover is disposed over the reflector cup.
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: August 14, 2018
    Assignee: RayVio Corporation
    Inventors: Douglas A. Collins, Li Zhang, Yitao Liao
  • Patent number: 10046077
    Abstract: Systems and methods for dissolving ozone gas in a liquid. An embodiment can comprise a tank having an upper region, a lower region, and a discharge outlet, all disposed in a specified geometry. A pump can be coupled with a liquid inlet in order to receive a liquid therefrom and to deliver the liquid via a pipe to the upper region of the tank. The pump can be coupled with the lower region of the tank in order to receive the liquid from the tank and to recirculate the liquid to the upper region of the tank. The apparatus can include an ozone inlet to receive ozone into the tank. The ozone inlet can comprise a venturi inlet disposed on the pipe downstream of the pump. The liquid can be released from the tank and depressurized, thereby providing for the ozone to emerge from the liquid as gas bubbles. The released liquid can be selected for a two-stage gas and aqueous cleaning process.
    Type: Grant
    Filed: July 7, 2016
    Date of Patent: August 14, 2018
    Inventor: Lee C. Ditzler
  • Patent number: 10046078
    Abstract: A system for applying a novel odor abating solution to an odor-emitting surface includes a storage compartment comprising a solution of iodine having a concentration of at least 0.0005% by total weight of the solution of I2; a misting system having mist nozzles that are supported over the odor-emitting surface, creating an aerial environment between the odor-emitting surface and the mist nozzles; misting nozzles configured to spray droplets of the solution into the aerial environment over the odor-emitting surface so that, in absence of any air movement exceeding 1 kilometer/hour, at least 75% of the droplets are suspended in the aerial environment over the odor-emitting surface for at least 10 seconds, allowing at least 1% by weight of the I2 in the solution to react with emitted odor before the 75% of the droplets are deposited on the odor-emitting surface. The odor-emitting surface may be within a waste transfer station.
    Type: Grant
    Filed: June 19, 2016
    Date of Patent: August 14, 2018
    Inventors: Kenneth R. Code, Joseph Provenzano
  • Patent number: 10046079
    Abstract: Clay composite sheets, mats, films or membranes without polymers. Methods of preparing clay composite sheets, mats, films or membranes without using polymers in the method. Methods of using clay composite sheets, mats, films or membranes prepared without using polymers. Antimicrobial dressing having organo-modified clay product. Transdermal delivery of drugs using organo-modified clay product and methods.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: August 14, 2018
    Inventors: Kausik Mukhopadhyay, Krishnaswamy Kasthuri Rangan, Tirumalai Srinivas Sudarshan
  • Patent number: 10046080
    Abstract: An absorbent article comprising a topsheet, an outer cover, at least one chassis component, and an absorbent core disposed between the topsheet and outer cover, wherein at least one of the outer cover or chassis component comprises a laminate comprising at least one nonwoven layer and at least one multilayer film, wherein the multilayer film has at least four layers and comprises at least one inner layer comprising one or more elastomeric components, at least one outer layer comprising a plastoelastic component, and at least one additional polymeric layer that is disposed next to an inner layer.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: August 14, 2018
    Assignee: The Procter & Gamble Company
    Inventors: Janet Neton, Jean-Philippe Marie Autran
  • Patent number: 10046081
    Abstract: The invention generally relates to dextran fibers which are preferably electrospun and devices formed from such fibers. In particular, such devices may include substances of interest (such as therapeutic substances) associated with the electrospun fibers. Upon exposure to a liquid the electrospun fibers dissolve immediately and the substances of interest are released into the liquid. Exemplary devices include bandages formed from electrospun dextran fibers and associated agents that promote hemostasis, such as thrombin and fibrinogen.
    Type: Grant
    Filed: July 29, 2014
    Date of Patent: August 14, 2018
    Assignees: The Henry M Jackson Foundation for the Advancement of Military Medicine, Inc., Virginia Commonwealth University
    Inventors: Gary Bowlin, David Simpson, James Bowman, Stephen Rothwell
  • Patent number: 10046082
    Abstract: Provided are a collagen sponge containing a drug for promoting fracture healing and a method for preparing the same, the method comprises the steps of: 1) adding bisphosphonate containing phosphonate radical in an equivalent dosage of 70 to 140 mg and/or strontium salt in a dosage of 100 to 800 mg into 1 kg of the enzymolysis solution of collagen; 2) adding a crosslinking agent into the solution, the crosslinking agent being added in a proportion where 40 to 60 U of crosslinking agent is added per gram of enzymolysis solution; 3) stirring the mixed solution in step 2) uniformly, then putting it into a stainless steel tray, and placing the tray in a vacuum lyophilizer for lyophilizing for 10 to 16 hours so that it is lyophilized into a sponge-like shape; and 4) allowing the collagen sponge in step 3) to be cut, packaged and sealed, and sterilized by irradiation with cobalt 60.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: August 14, 2018
    Assignee: WUHAN VSD MEDICAL SCIENCE & TECHNOLOGY CO., LTD.
    Inventors: Yansong Liu, Yingze Zhang, Zhidao Xia, Hongxia Guan
  • Patent number: 10046083
    Abstract: The disclosure relates to polyurethane and polyureaurethane based putty compositions which harden into a fully cured solid form at room temperature and body temperature and are suitable for use as a bone cement, bone substitute, hard tissue adhesive, or bone hemostatic agent.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: August 14, 2018
    Assignee: Abyrx, Inc.
    Inventors: Rao Bezwada, Aniq Darr, Richard L. Kronenthal, John Pacifico
  • Patent number: 10046084
    Abstract: This invention provides aragonite- and calcite-based scaffolds for the repair, regeneration, enhancement of formation or a combination thereof of cartilage and/or bone, which scaffolds comprise at least two phases, wherein each phase differs in terms of its chemical content, or structure, kits comprising the same, processes for producing solid aragonite or calcite scaffolds and methods of use thereof.
    Type: Grant
    Filed: March 1, 2016
    Date of Patent: August 14, 2018
    Assignee: CARTIHEAL (2009) LTD.
    Inventors: Nir Altschuler, Razi Vago
  • Patent number: 10046085
    Abstract: Embodiments of the invention provide compositions include bio degradable polymers, medical implants fabricated from these compositions and methods of using such implants. Many embodiments provide medical implants including a first polymer backbone having a first rate of biodegradation and a second polymer backbone having a second rate of biodegradation faster than the first rate. In some embodiments, the second backbone is configured to be replaced by a natural tissue layer. The first backbone provides a scaffold for the implant while the second backbone degrades. This scaffold can enhance mechanical properties of the implant including various aspects of mechanical strength such as tensile, bending, hoop and yield strength; and elasticity. The scaffold also serves to maintain a minimum level of structural support of the implant during the period of degradation of the second backbone or for the entire life of the implant so that the implant does not mechanically fail.
    Type: Grant
    Filed: June 1, 2010
    Date of Patent: August 14, 2018
    Assignee: InCube Labs, LLC
    Inventors: Mir Imran, Sanjay Patel, Joel Harris
  • Patent number: 10046086
    Abstract: A biodegradable scaffold, a low-molecular weight thioketal, and a method of forming a biodegradable scaffold are provided. The biodegradable scaffold includes a thioketal and an isocyanate, where the thioketal is linked to the isocyanate to form the scaffold. The low-molecular weight thioketal includes 2,2-dimethoxypropane and thioglycolic acid, wherein the thioketal includes at least two hydroxyl terminal groups. The method of forming the biodegradable scaffold includes blending a thioketal with an excess isocyanate, forming a quasi-prepolymer, mixing the thioketal, the quasi-prepolymer, and a ceramic, and then adding a catalyst to form the biodegradable scaffold. The thioketal is a low-molecular weight thioketal having at least two hydroxyl terminal groups.
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: August 14, 2018
    Assignee: Vanderbilt University
    Inventors: Scott A. Guelcher, Madison McGough, Mukesh K. Gupta, Craig L. Duvall, John Martin, Jon Page
  • Patent number: 10046087
    Abstract: There are provided collagen based polymeric materials comprising collagen molecules and/or collagen derived molecules which have been functionalized by the addition of one or more ethylenically unsaturated moieties and which have been cross-linked via said moieties. Also provided are collagen based compositions and methods of producing collagen based polymeric materials.
    Type: Grant
    Filed: March 21, 2014
    Date of Patent: August 14, 2018
    Assignee: University of Leeds
    Inventors: Giuseppe Tronci, Stephen John Russell, David John Wood
  • Patent number: 10046088
    Abstract: Nano scale collagen particles can be obtained from an embrittling and attrition process that reduces the size of collagen particles to the nano scale. These nano scale collagen particles have many favorable properties such as providing beneficial and enhanced properties for cell seeding and wound healing. The nano scale collagen particles can be included in biocompatible (e.g., biostable or biodegradable) compositions and are useful for wound treatment and management, as well as in cell cultures and tissue engineering implants.
    Type: Grant
    Filed: January 27, 2015
    Date of Patent: August 14, 2018
    Assignee: EMPIRE TECHNOLOGY DEVELOPMENT LLC
    Inventors: Hengky Chang, Henry Leung
  • Patent number: 10046089
    Abstract: The present invention relates to a novel bone graft and methods for producing the graft. The bone graft can be used for surgical, plastic and/or cosmetic bone replacement for a patient in need thereof. The bone graft is made of a scaffold or matrix of sheet material having a 3-dimensional pattern of a continuous network of voids and/or indentations for enhancing new bone growth.
    Type: Grant
    Filed: May 7, 2013
    Date of Patent: August 14, 2018
    Inventor: Timothy Ganey
  • Patent number: 10046090
    Abstract: Bone particle compositions and kits are provided that include a biologically-resorbable cement and a plurality of processed bone particles. A first portion of the processed bone particles in the compositions have a shape configured to interconnect with one another, while a second portion of the processed bone particles having an irregular shape. Methods for treating a bone defect are also provided wherein an effective amount of the bone particle compositions are administered to a site of a bone defect in a subject.
    Type: Grant
    Filed: October 8, 2014
    Date of Patent: August 14, 2018
    Assignee: VIVORTE, INC.
    Inventor: Robert L. Burden, Jr.
  • Patent number: 10046091
    Abstract: Embodiments disclosed herein related to a printing system configured to print a three-dimensional object on a region of interest. The printing system can include one or more steerable actuators that are coupled to and configured to controllably steer the one or more dispense elements. Other embodiments disclosed herein also relate to methods of using such printing systems.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: August 14, 2018
    Assignee: ELWHA LLC
    Inventors: Roderick A. Hyde, Elizabeth A. Sweeney, Jordin T. Kare
  • Patent number: 10046092
    Abstract: The present invention is related to scoring or cutting balloon catheters carrying at least on a portion of their surface at least one oxidation-insensitive drug or oxidation-insensitive polymer-free drug preparation and at least one lipophilic antioxidant at a ratio of 3-100% by weight of the at least one lipophilic antioxidant in relation to 100% by weight of the drug, wherein the at least one oxidation-insensitive drug is selected of taxanes, thalidomide, statins, corticoids and lipophilic derivatives of corticoids, and the at least one lipophilic antioxidant is selected of nordihydroguaiaretic acid, resveratrol and propyl gallate.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: August 14, 2018
    Assignee: The SPECTRANETICS CORPORATION
    Inventors: Ulrich Speck, Madeleine Caroline Berg